Zydus Lifesciences Limited (BOM:532321)

Market Cap	885.74B
Revenue (ttm)	222.47B
Net Income (ttm)	45.37B
Shares Out	n/a
EPS (ttm)	45.03
PE Ratio	19.52
Forward PE	n/a
Dividend	3.00 (0.36%)
Ex-Dividend Date	Jul 26, 2024

Volume	52,991
Average Volume	104,107
Open	865.10
Previous Close	868.20
Day's Range	861.95 - 886.80
52-Week Range	797.05 - 1,323.90
Beta	n/a
RSI	51.03
Earnings Date	May 16, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 26,921
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2023, Zydus Lifesciences's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.